Paclitaxel resistant MDA-MB-231 Cells and resensitization with bexarotene treatment
收藏官方服务：
资源简介：
Paclitaxel resistant MDA-MB-231 Cells and resensitization with bexarotene treatment
应用场景：
创建时间：
2011-07-18
相关数据集
Suppression of adaptive responses to targeted cancer therapy by transcriptional repression [RNA-seq]. Homo sapiens
Large-scale genomic profiling efforts have facilitated the characterization of molecular alterations in cancers and aided the development of targeted kinase inhibitors for a wide array of cancer types
NIAID Data Ecosystem50
A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated myeloid malignancies
A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated myeloid malignancies
NIAID Data Ecosystem30
SAKE (Single-cell RNA-Seq Analysis and Klustering Evaluation) Identifies Markers of Resistance to Targeted BRAF Inhibitors in Melanoma Cell Populations. Homo sapiens isolate:451Lu is a selected xenograft aggressive metastatic sub-line of WM164. WM164 is a metastatic human melanoma cell line established from a metastatic site (right upper arm) in a 22-year-old male with stage IV superficial spreading melanoma. 451Lu cell line features the specific V600E (Val600Glu) mutation at codon 600 in the BRAF gene.
The goal of this study is to apply the SAKE algorithms to identify drug-resistant cellular populations as human melanoma cells respond to targeted BRAF inhibitors. Single-cell RNA-Seq data from 10x Ge
NIAID Data Ecosystem20
YAP activation mediates acquired resistance to ALK inhibitor in ALK rearranged non–small cell lung cancer
To investigate a possible candidate for overcoming the acquired resistance to ALK-TKI, we established an in vitro model of acquired resistance to crizotinib (H3122-CR) by exposing EML4-ALK–positive H3
NIAID Data Ecosystem40
Divergent BRAF Inhibitor Resistance Mechanisms Revealed through Epigenetic Mapping. Divergent BRAF Inhibitor Resistance Mechanisms Revealed through Epigenetic Mapping
In this report, we generated eight matched pairs of vemurafenib sensitive/resistant melanoma lines and subjected these to concurrent RNA-seq and H3K27Ac ChIP-seq analysis. Globally, we identified two
NIAID Data Ecosystem30
